Breaking News Instant updates and real-time market news.

KPTI

Karyopharm

$8.90

2.37 (36.29%)

07:19
07/05/19
07/05
07:19
07/05/19
07:19

Karyopharm approval label for Xpovio 'compelling,' says H.C. Wainwright

Karyopharm Therapeutics on Wednesday, three days before the action date date, announced that the FDA granted accelerated approval for Xpovio n relapsed or refractory multiple myeloma patients who have received at least four prior therapies and whose disease was refractory after at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody, H.C. Wainwright analyst Edward White tells investors in a research note. Further, there is not a black box warning or contraindications in the Xpovio label, adds the analyst. He finds the label "compelling and inline with expectations." White estimates Xpovio in the penta-refractory setting will have sales of $5.5less than this year rising to $123.8M in 2026. He keeps a Buy rating on Karyopharm Therapeutics with a $32 price target.

  • 06

    Jul

KPTI Karyopharm
$8.90

2.37 (36.29%)

02/28/19
HCWC
02/28/19
NO CHANGE
Target $30
HCWC
Buy
H.C. Wainwright says selinexor expectations not changed by ODAC recommendation
After the FDA's Oncologic Drugs Advisory Committee, or ODAC, voted on February 26 to recommend that the FDA wait for the Phase 3 BOSTON trial results before deciding on selinexor's NDA application, H.C. Wainwright analyst Edward White noted that the decision was not unanimous and said "the FDA typically but does not always follow the ODAC panel's recommendations." It is possible that a delay to wait for the BOSTON data could push out a selinexor launch by one year or more, but the ODAC recommendation is "not changing our expectations," stated White, who keeps a Buy rating and $30 price target on shares of Karyopharm.
03/01/19
JPMS
03/01/19
DOWNGRADE
Target $7
JPMS
Neutral
Karyopharm downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Eric Joseph downgraded Karyopharm Therapeutics to Neutral and lowered his price target for the shares to $7 from $21. The analyst sees a "rocky regulatory road" forward for the company.
03/15/19
WEDB
03/15/19
NO CHANGE
WEDB
Wedbush views Karyopharm 's PDUFA date extension as a positive
Wedbush analyst David Nierengarten maintained an Outperform rating and $6 price target on Karyopharm. In a note titled "FDA Extends PDUFA by Three Months," he said he is inclined to view the extension as a positive for the company "given the negative sentiment on the name and general belief that an April 6, 2019 approval was unlikely."
06/14/19
HCWC
06/14/19
NO CHANGE
Target $29
HCWC
Buy
Karyopharm EHA Phase 1b/2 combination data 'encouraging,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $29 price target on Karyopharm, saying the company presented "encouraging" early Phase 1b/2 selinexor combination data from the STOMP trial in relapsed or refractory multiple myeloma patients at the European Hematological Association 2019 Annual Meeting. In a research note to investors, White says the updated selinexor with Darzalex data "continues to look good," with efficacy results showing an overall response rate of 73% in Darzalex naive patients versus the EHA abstract data published last month with an ORR of 77%. Looking ahead, White projects revenues of $189M and $241M for selinexor in penta-refractory multiple myeloma and DLBCL, respectively, in 2026. For selinexor in combination multiple myeloma treatment, he forecasts revenues of $332M in 2026, and for selinexor in solid tumors he sees revenues of $241M in 2026.

TODAY'S FREE FLY STORIES

LMT

Lockheed Martin

$357.57

0.675 (0.19%)

07:32
07/23/19
07/23
07:32
07/23/19
07:32
Earnings
Lockheed Martin raises FY19 EPS view to $20.85-$21.15 from $20.05-$20.35 »

Consensus is $20.57.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

INGR

Ingredion

$80.40

-0.705 (-0.87%)

07:32
07/23/19
07/23
07:32
07/23/19
07:32
Recommendations
Ingredion analyst commentary  »

Ingredion price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 22

    Aug

  • 19

    Sep

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

07:32
07/23/19
07/23
07:32
07/23/19
07:32
Earnings
Kimberly-Clark raises FY19 adj. EPS view to $6.65-$6.80 from $6.50-$6.70 »

FY19 consensus $6.72. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SEDG

SolarEdge

$63.08

-0.2 (-0.32%)

07:31
07/23/19
07/23
07:31
07/23/19
07:31
Recommendations
SolarEdge analyst commentary  »

SolarEdge price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

LMT

Lockheed Martin

$357.57

0.675 (0.19%)

07:31
07/23/19
07/23
07:31
07/23/19
07:31
Earnings
Lockheed Martin reports Q2 EPS $5.00, consensus $4.77 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

07:30
07/23/19
07/23
07:30
07/23/19
07:30
Recommendations
Cadence Design analyst commentary  »

Cadence Design price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

07:30
07/23/19
07/23
07:30
07/23/19
07:30
Earnings
Kimberly-Clark reports Q2 adjusted EPS $1.67, consensus $1.61 »

Reports Q2 revenue $4.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

T

AT&T

$32.14

-0.63 (-1.92%)

07:30
07/23/19
07/23
07:30
07/23/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 30

    Jul

  • 08

    Aug

WDDMF

WeedMD

$0.00

(0.00%)

07:30
07/23/19
07/23
07:30
07/23/19
07:30
Hot Stocks
WeedMD launches cannabis extraction affiliate CX Industries »

WeedMD announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKG

Asanko Gold

$0.83

0.0341 (4.29%)

, GFI

Gold Fields

$5.51

-0.16 (-2.82%)

07:28
07/23/19
07/23
07:28
07/23/19
07:28
Hot Stocks
Asanko Gold outlines 2H19 exploration program »

Asanko Gold (AKG)…

AKG

Asanko Gold

$0.83

0.0341 (4.29%)

GFI

Gold Fields

$5.51

-0.16 (-2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADPT

Adaptive Biotechnologies

$39.16

0.61 (1.58%)

, MSFT

Microsoft

$138.41

1.79 (1.31%)

07:27
07/23/19
07/23
07:27
07/23/19
07:27
Initiation
Adaptive Biotechnologies, Microsoft, Roche initiated  »

Adaptive Biotechnologies…

ADPT

Adaptive Biotechnologies

$39.16

0.61 (1.58%)

MSFT

Microsoft

$138.41

1.79 (1.31%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 02

    Sep

  • 09

    Sep

  • 04

    Nov

NDAQ

Nasdaq

$101.77

0.05 (0.05%)

07:26
07/23/19
07/23
07:26
07/23/19
07:26
Hot Stocks
Nasdaq signs new agreement with Football Index »

Nasdaq announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

LII

Lennox

$264.15

-14.91 (-5.34%)

07:25
07/23/19
07/23
07:25
07/23/19
07:25
Recommendations
Lennox analyst commentary at Credit Suisse »

Lennox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

07:25
07/23/19
07/23
07:25
07/23/19
07:25
Hot Stocks
Breaking Hot Stocks news story on Marinus Pharmaceuticals »

Marinus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$2.56

-0.04 (-1.54%)

07:23
07/23/19
07/23
07:23
07/23/19
07:23
Recommendations
Sorrento Therapeutics analyst commentary at H.C. Wainwright »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$147.16

1.98 (1.36%)

07:23
07/23/19
07/23
07:23
07/23/19
07:23
Recommendations
Hershey analyst commentary at Wells Fargo »

Hershey price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

INAP

Internap

$2.76

-0.23 (-7.69%)

07:21
07/23/19
07/23
07:21
07/23/19
07:21
Hot Stocks
Internap launches Intelligent Monitoring managed cloud and monitoring service »

Internap Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLAB

Silicon Labs

$105.16

1.14 (1.10%)

07:21
07/23/19
07/23
07:21
07/23/19
07:21
Initiation
Silicon Labs initiated at Benchmark »

Silicon Labs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 13

    Sep

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

07:21
07/23/19
07/23
07:21
07/23/19
07:21
Downgrade
Viveve rating change at Mizuho »

Mizuho double downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$54.64

-0.25 (-0.46%)

07:20
07/23/19
07/23
07:20
07/23/19
07:20
Recommendations
Mondelez analyst commentary at Wells Fargo »

Mondelez price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

INTC

Intel

$51.36

1.1 (2.19%)

07:19
07/23/19
07/23
07:19
07/23/19
07:19
Initiation
Intel initiated at Benchmark »

Intel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 03

    Aug

TORC

ResTORbio

$11.18

1.15 (11.47%)

07:19
07/23/19
07/23
07:19
07/23/19
07:19
Hot Stocks
ResTORbio completes patient enrollment of Phase 3 PROTECTOR 1 trial »

resTORbio announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$264.15

-14.91 (-5.34%)

07:18
07/23/19
07/23
07:18
07/23/19
07:18
Recommendations
Lennox analyst commentary at Wells Fargo »

Lennox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

AGTC

Applied Genetic

$3.89

0.02 (0.52%)

07:18
07/23/19
07/23
07:18
07/23/19
07:18
Hot Stocks
Applied Genetic completes enrollment of third group in Phase 1/2 clinical study »

Applied Genetic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

PEBO

Peoples Bancorp

$31.80

0.08 (0.25%)

07:18
07/23/19
07/23
07:18
07/23/19
07:18
Earnings
Peoples Bancorp reports Q2 EPS 46c with items, consensus 68c »

Reports Q2 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.